Symbols

CRVO

CervoMed·NASDAQ

--(--)

CRVO Profile

Cervomed Inc.

A company that developing standard-of-care therapies for treatment-resistant solid cancerous tumors

Industry

Biological Technology

Established Date

01/10/1995

Listing Date

11/09/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cervomed.com

Security Type

Common stock

Office address

20 Park Plaza, Suite 424, Boston, Massachusetts 02116

Business

Introduction

CervoMed Inc., was originally incorporated under the laws of Nevada on January 10, 1995 and re-incorporated in Delaware on June 18, 2015. The company is a clinical-stage biotechnology company focused on developing treatments for age-related neurological diseases. Their lead drug candidate, neflamapimod, is an oral small molecule drug in development that can easily cross the blood-brain barrier and selectively inhibit the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction. By targeting key pathological processes in brain degenerative diseases, neflamapimod is expected to reverse synaptic dysfunction, improve neuronal health, and delay or stop disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies (DLB), its main indication, as well as non-fluent primary progressive aphasia (nfvPPA), rheumatoid arthritis (RAS) and amyotrophic lateral sclerosis (ALS).